References
- Yeo W, Chan P K, Zhong S, Ho W M, Steinberg J L, Tam J S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307
- Lok A, McMahon B J. AASLD practice guidelines: chronic hepatitis B. Hepatology 2001; 34: 1225–1241
- BC Cancer Agency. 042 Hepatitis B screening and prophylaxis in breast cancer. 2005, http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Management/HepBScreening.htm
- Kojiro T. Lamivudine therapy. Consensus of Liver Diseases 2002, M Yano. Japan Medical Center, Tokyo 2002; 86–94
- Yeo W, Johnson P J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220
- Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2004; 346: 235–242
- Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
- Mindikoglu A L, Regev A, Schiff E R. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076–1081